A breast cancer diagnosis often begins with a biopsy, but identifying cancer is only the first step in understanding the disease. Before treatment begins, physicians can learn a considerable amount about a tumor by examining its cells, tissue structure, and biological characteristics.
These findings help explain why two people with breast cancer may receive very different treatment recommendations, even when their tumors appear similar on imaging.
Modern breast pathology provides information that extends beyond determining whether a tissue sample is benign or malignant. By identifying a tumor’s specific characteristics, pathologists help other physicians understand the disease and evaluate treatment options.
Dr. Robert Guarino, a physician specializing in breast pathology with advanced fellowship training at The Mount Sinai Hospital in New York City, emphasizes the importance of understanding what tissue examination can reveal about breast cancer before treatment decisions are made.
The First Question: What Type of Breast Cancer Is Present?
Breast cancer is not a single disease. Several different types can develop within breast tissue, and identifying the specific type is an important part of the diagnostic process.
When a pathologist performs a biopsy, they examine thin sections of tissue under a microscope. The arrangement of cells, their appearance, and their relationship to surrounding structures provide clues about the nature of the abnormality.
One of the most common diagnoses is invasive breast carcinoma of no special type, historically referred to as invasive ductal carcinoma. Other forms, including invasive lobular carcinoma, have different microscopic features and growth patterns.
Pathologists also distinguish between invasive cancer and ductal carcinoma in situ, commonly called DCIS.
DCIS involves abnormal cells confined within the breast ducts, with no evidence of invasion into the surrounding breast tissue. Invasive breast cancer, by contrast, has extended beyond the structures where it originated.
This distinction matters because the two conditions have different clinical implications and treatment considerations.
Identifying the histologic type provides a foundation for the additional testing and evaluation that follow.
What the Appearance of Cancer Cells Can Tell Physicians
After identifying the cancer type, pathologists examine how the tumor cells are organized and how they differ from normal breast cells.
This assessment helps determine the tumor’s histologic grade.
For many invasive breast cancers, grading involves evaluating three characteristics: the degree of gland or tubule formation, the appearance of cell nuclei, and the number of dividing cells observed.
Tumors that retain more features of normal breast tissue generally receive a lower grade. Tumors with more pronounced cellular abnormalities and increased proliferative activity may receive a higher grade.
Grade provides information about the tumor’s biological characteristics and may contribute to prognosis estimates.
However, grade does not determine how a cancer will behave on its own. Physicians must consider it alongside other findings, including tumor extent, lymph node involvement, and biological markers.
A small tumor may have a high grade, while a larger tumor may have a lower grade. This is one reason the appearance of cancer cells can provide information that measurements alone cannot capture.
Why Hormone Receptor Testing Matters
Some of the most important information obtained from a breast cancer biopsy comes from tests that identify specific proteins within the tumor cells.
Estrogen receptor and progesterone receptor testing helps determine whether a cancer expresses receptors associated with hormonal signaling.
These tests are commonly performed using immunohistochemistry, a laboratory technique that uses antibodies to identify particular proteins in tissue.
When breast cancer cells express estrogen receptors, they may respond to treatments that interfere with estrogen signaling.
Depending on the clinical circumstances, hormone receptor-positive breast cancers may be treated with endocrine therapies designed to reduce or block the effects of hormones on cancer cells.
Hormone receptor testing does not establish a treatment plan on its own. However, it provides information that can help physicians determine which therapies may be appropriate.
Physicians interpret the results alongside the patient’s other clinical and pathological findings.
Understanding the Role of HER2
HER2 is another important biological marker evaluated in invasive breast cancer.
HER2 is a protein involved in cell growth signaling. Some breast cancers have higher levels of this protein or additional copies of the gene that produces it.
These cancers are classified as HER2-positive when testing meets established criteria.
Identifying HER2-positive disease is important because certain treatments specifically target HER2-related signaling.
Testing typically begins with immunohistochemistry, although additional testing may be required when results are not definitive.
A common follow-up method is in situ hybridization, which can assess whether the HER2 gene is amplified.
The distinction between HER2-positive and HER2-negative disease has important treatment implications.
It also illustrates how breast pathology has developed beyond traditional microscopic examination. Modern evaluation combines tissue appearance with biological testing to provide a more detailed understanding of cancer.
What Can Be Learned From a Needle Biopsy?
Many breast cancers are initially diagnosed through a core needle biopsy.
During this procedure, doctors collect small tissue samples from an area of concern. These samples allow a pathologist to examine the abnormality and, in many cases, perform the testing needed to establish an initial diagnosis.
A core biopsy can often identify the histologic type of an invasive cancer, assess grade, and establish hormone receptor and HER2 status.
This information may be available before a patient undergoes surgery or begins systemic treatment.
In some circumstances, treatment may begin before surgical removal of the tumor. This approach, known as neoadjuvant therapy, may be recommended based on the cancer’s characteristics and the patient’s clinical situation.
Information obtained from the initial biopsy can therefore be important in determining the sequence of treatment.
However, a needle biopsy samples only part of a larger area.
It may not fully represent every feature of the tumor, particularly when different regions have different characteristics.
Some findings, including the complete extent of invasive disease or the status of surgical margins, may require examination of a larger surgical specimen.
Recognizing these limitations is important when interpreting an initial pathology report.
Why Additional Information May Still Be Needed
Although an initial biopsy can reveal substantial information, it cannot answer every question about a breast cancer diagnosis.
Physicians may still need imaging studies to evaluate the extent of disease, clinical examination to assess relevant findings, or additional procedures to investigate lymph nodes.
Some patients may also be candidates for genomic assays that evaluate patterns of gene expression within a tumor.
In selected clinical situations, these tests can help estimate recurrence risk or provide additional information relevant to treatment decisions.
They are not appropriate for every breast cancer diagnosis, and their usefulness depends on factors such as tumor type, stage, and receptor status.
Additional information may also become available after surgery, when the pathologist can examine more tissue.
The diagnostic process is therefore often progressive. Each stage contributes information that helps physicians develop a more complete understanding of the disease.
How Early Pathology Findings Influence Treatment Planning
The information obtained before treatment begins can help physicians evaluate several possible approaches to care.
A hormone receptor-positive cancer may have treatment options that differ from those considered for HER2-positive or triple-negative disease.
Tumor grade, clinical stage, patient health, and other factors may also influence whether treatment begins with surgery or systemic therapy.
The treating medical team makes these decisions in consultation with the patient.
Pathology provides essential information, but it is one component of a broader clinical assessment.
The goal is to understand the cancer’s characteristics well enough to select an appropriate approach rather than assuming that every breast cancer should be managed in the same way.
A Diagnosis Contains More Information Than a Name
For patients, receiving a breast cancer diagnosis can be overwhelming. Medical terms such as histologic grade, hormone receptor status, and HER2 may initially seem difficult to understand.
Yet these details have a purpose.
They help physicians distinguish between cancers that may look similar at first but have different biological characteristics and treatment considerations.
A biopsy can reveal the type of cancer present, how its cells appear under the microscope, and whether certain biological markers are expressed. Additional testing and clinical evaluation can then build on those findings.
The result is a more detailed picture of the disease before treatment begins.
As breast cancer diagnosis and treatment continue to develop, understanding the individual characteristics of a tumor remains central to informed medical decision-making. The information found within a small tissue sample can play an important role in shaping the next steps of care.
